Macrolide Resistance in Streptococcus Pharyngitis
Macrolide resistance in Group A Streptococcus (GAS) pharyngitis varies dramatically by geographic region and time period, ranging from as low as 4-8% in some areas to as high as 15% or more in others, with significant temporal fluctuations driven by clonal shifts in circulating strains. 1
Geographic and Temporal Variation
The prevalence of macrolide resistance is highly variable and region-specific:
Low resistance regions: Recent data from Italy (2012-2013) showed resistance rates of 7.4% 2, while Korea (2009) reported 4.6% 3. Botswana data noted "concerns about macrolide resistance" but maintained full penicillin susceptibility 4.
Moderate resistance regions: A U.S. primary care study (2011-2015) from Wisconsin found 15% of GAS isolates were nonsusceptible to both erythromycin and clindamycin, with an additional 12% showing inducible resistance 5.
Dynamic resistance patterns: Portugal experienced a surge to 9% resistance in 2019, driven by rapid expansion of a specific mef(A)-msr(D)-positive emm2-ST55 lineage that replaced previous resistant strains 6.
Key Clinical Implications
The IDSA guidelines explicitly note that resistance of GAS to macrolides (azithromycin and clarithromycin) is well-known and varies geographically and temporally 1. This geographic variability makes it impossible to provide a single universal resistance rate.
Important Resistance Mechanisms
Macrolide resistance occurs through two main mechanisms:
- M phenotype (mef(A) gene): Efflux-mediated resistance, typically 37-41% of resistant strains 2, 3
- cMLSB phenotype (erm(B) gene): Ribosomal modification causing cross-resistance to clindamycin, typically 52-62% of resistant strains 2, 3
- iMLSB phenotype (erm(A) gene): Inducible resistance detected by D-test 2
Critical Pitfalls to Avoid
Clonal dynamics matter more than antibiotic consumption: The dramatic decline in erythromycin resistance in Korea (from 44.8% in 2002 to 4.6% in 2009) occurred despite increasing macrolide production, driven instead by disappearance of the resistant emm12 genotype 3. Similarly, Italy's resistance decline occurred with stable macrolide consumption 2.
Azithromycin shows inferior efficacy: Recent network meta-analysis data demonstrate azithromycin has significantly lower bacterial eradication rates compared to penicillin V (OR: 0.53 for early eradication, OR: 0.38 for late eradication), along with higher recurrence rates and increased adverse events 7.
Resistance patterns shift rapidly: Portugal's experience shows how a single resistant clone can cause resistance rates to spike within a single year 6.
Practical Recommendations
Penicillin V remains the first-line treatment with strong recommendation 1, as all studies consistently report 100% penicillin susceptibility 4, 2, 3.
When macrolides are considered for penicillin-allergic patients:
- Use only for patients with substantial manifestations of penicillin hypersensitivity 5
- Always perform susceptibility testing when macrolides are used 5
- Consider cephalosporins (cefdinir, cefpodoxime) as superior alternatives if no immediate-type hypersensitivity exists 1, 7
- Clindamycin remains an effective alternative for true penicillin allergy 1
The guideline designation of macrolides as having only "moderate" quality evidence reflects this resistance concern 1, contrasting with the "high" quality designation for penicillin-based regimens.